	US 12,220,391 B2
	Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
Naji Abumrad, Nashville, TN (US); John Rathmacher, Story City, IA (US); and Shawn Baier, Polk City, IA (US)
Assigned to Metaolic Technologies, LLC, Missoula, MT (US)
Filed by Metabolic Technologies, LLC, Missoula, MT (US)
Filed on Aug. 8, 2022, as Appl. No. 17/882,905.
Application 17/882,905 is a continuation of application No. 16/284,810, filed on Feb. 25, 2019, granted, now 11,406,609.
Application 16/284,810 is a continuation in part of application No. 15/411,303, filed on Jan. 20, 2017, granted, now 10,213,399, issued on Feb. 26, 2019.
Claims priority of provisional application 62/281,561, filed on Jan. 21, 2016.
Prior Publication US 2023/0028151 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/191 (2006.01); A61P 3/04 (2006.01); A61P 21/00 (2006.01)

CPC A61K 31/191 (2013.01) [A61P 3/04 (2018.01); A61P 21/00 (2018.01)]

8 Claims

1. A method for inhibiting or treating a disease, a condition or a disorder responsive to autophagy modulation in adipocytes comprising administering to an animal in need thereof an effective amount of a composition of β-hydroxy-β-methylbutyric acid (HMB).